ABL Bio Secures $55 Million from Eli Lilly for Grabody Bispecific Antibody Platform Development
核心洞察
ABL Bio (搜索) received $40 million upfront payment and $15 million equity investment from Eli Lilly for licensing and collaboration on its Grabody bispecific antibody platform.
The partnership enables joint research and development on multiple therapeutic candidates across various modalities, with a total deal value of $2.602 billion.
ABL Bio (搜索) plans to expand Grabody platform indications into obesity (搜索) and muscle disorders (搜索) while advancing next-generation ADC programs and combination therapies.
ABL Bio (搜索), a South Korean bispecific antibody specialist, has secured $55 million in funding from Eli Lilly and Company through a comprehensive licensing and collaboration agreement for its proprietary Grabody platform. The deal includes a $40 million upfront payment and $15 million equity investment, marking a significant milestone in the development of next-generation bispecific antibody therapeutics.
Strategic Partnership Expands Therapeutic Horizons
The collaboration between ABL Bio (搜索) and Lilly encompasses joint research and development on multiple therapeutic candidates leveraging the Grabody platform across various modalities. The partnership, formalized through agreements signed on November 12 and 14, carries a total potential value of $2.602 billion, including the initial upfront payment.
Sang Hoon Lee, CEO of ABL Bio (搜索), outlined the company's strategic priorities following the completion of administrative procedures including the HSR Act. "The company plans to use the newly secured funding to expand the indications of its Grabody platform into high-unmet-need areas such as obesity (搜索) and muscle disorders (搜索)," Lee stated. "ABL Bio also intends to extend clinical development of its bispecific immuno-oncology candidates into combination therapies and focus on advancing next-generation ADC programs."
Robust Clinical Pipeline Demonstrates Platform Versatility
ABL Bio (搜索)'s clinical portfolio showcases the versatility of its Grabody platform, with eight pipelines currently in development across multiple therapeutic areas. The company's clinical projects include ABL301 (SAR446159), ABL001 (tovecimig), ABL111 (givastomig), ABL503 (ragistomig), ABL105 (YH32367), ABL104 (YH32364), ABL103, and ABL202 (CS5001/LCB71), spanning indications in the United States, China, Australia, and Korea.
Several programs have achieved notable regulatory and clinical milestones. ABL001 (tovecimig) has received Fast Track designation from the U.S. Food and Drug Administration, recognizing its potential to address unmet medical needs. Following completion of the Phase 1 clinical trial of ABL301 (SAR446159), Sanofi will conduct subsequent clinical studies, demonstrating the platform's appeal to major pharmaceutical partners.
Advanced Combination Therapy Approaches Show Promise
The company's commitment to combination therapy development is exemplified by ABL111 (givastomig), co-developed with NovaBridge (搜索). This bispecific antibody has presented encouraging data from a Phase 1b clinical trial evaluating triple combination therapy with nivolumab and chemotherapy, with results presented at ESMO GI 2025.
Next-Generation ADC Technology Development
Beyond traditional bispecific antibodies, ABL Bio (搜索) is advancing its technological capabilities in antibody-drug conjugates. The company is developing both bispecific ADCs and dual-payload ADCs, representing innovative approaches to targeted cancer (搜索) therapy. These next-generation ADC programs will benefit from the newly secured funding and Lilly's collaborative expertise.
The partnership positions ABL Bio (搜索) to accelerate development across its core technology platforms while exploring new therapeutic areas with significant unmet medical needs. The collaboration framework enables long-term therapeutic development opportunities, leveraging both companies' complementary strengths in bispecific antibody research and clinical development.